FibroBiologics to Present at the 2025 ThinkEquity Conference
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 2025 ThinkEquity Conference on October 30, 2025 at the Mandarin Oriental, New York City. The company presentation is scheduled for 4:30 p.m. ET on October 30, and management will be available for one-on-one investor meetings throughout the event.
For presentation details or to request a meeting, contact the company via its website or email info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG) ha annunciato che il fondatore e CEO Pete O’Heeron farà una presentazione al ThinkEquity Conference 2025 il 30 ottobre 2025 presso il Mandarin Oriental di New York. La presentazione dell'azienda è prevista per le 16:30 ET del 30 ottobre, e il management sarà disponibile per incontri con investitori uno-a-uno durante l'evento.
Per dettagli sulla presentazione o per richiedere un incontro, contattare l'azienda tramite il suo sito web o via email info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG) anunció que el fundador y CEO Pete O’Heeron presentará en la Conferencia ThinkEquity 2025 el 30 de octubre de 2025 en el Mandarin Oriental, Nueva York. La presentación de la empresa está programada para las 4:30 p.m. ET del 30 de octubre, y la dirección estará disponible para reuniones individuales con inversores durante el evento.
Para detalles de la presentación o para solicitar una reunión, contacte a la empresa a través de su sitio web o por correo electrónico a info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG)는 창립자 겸 최고경영자 Pete O’Heeron이 2025 ThinkEquity Conference에서 2025년 10월 30일 미국 뉴욕의 Mandarin Oriental에서 발표할 것이라고 발표했습니다. 회사 발표는 10월 30일 오후 4:30 ET로 예정되어 있으며 경영진은 행사 전 기간 동안 일대일 투자자 미팅을 가질 예정입니다.
발표 세부 정보 또는 미팅 요청은 회사의 웹사이트 또는 info@fibrobiologics.com로 이메일로 문의하십시오.
FibroBiologics ( Nasdaq : FBLG ) a annoncé que le fondateur et PDG Pete O’Heeron présentera lors de la ThinkEquity Conference 2025 le 30 octobre 2025 au Mandarin Oriental, New York. La présentation de l’entreprise est prévue pour 16h30 ET le 30 octobre, et la direction sera disponible pour des réunions individuelles avec les investisseurs tout au long de l’événement.
Pour les détails de la présentation ou pour demander une réunion, contactez l’entreprise via son site Web ou par e-mail à info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG) gab bekannt, dass der Gründer und CEO Pete O’Heeron bei der 2025 ThinkEquity Conference am 30. Oktober 2025 im Mandarin Oriental in New York auftreten wird. Die Unternehmenspräsentation ist für 16:30 Uhr ET am 30. Oktober vorgesehen, und das Management wird während der Veranstaltung für Einzelgespräche mit Investoren zur Verfügung stehen.
Für Details zur Präsentation oder um ein Treffen zu vereinbaren, kontaktieren Sie das Unternehmen über seine Website oder per E-Mail an info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG) أعلنت أن المؤسس والرئيس التنفيذي Pete O’Heeron سيقدم في مؤتمر ThinkEquity 2025 في 30 أكتوبر 2025 في فندق Mandarin Oriental بمدينة نيويورك. العرض الخاص بالشركة مبرمج لـ 4:30 مساءً بتوقيت شرق الولايات المتحدة في 30 أكتوبر، وستكون الإدارة متاحة للاجتماعات الفردية مع المستثمرين طوال الحدث.
للاطلاع على تفاصيل العرض أو لطلب اجتماع، تواصل مع الشركة عبر موقعها الإلكتروني أو عبر البريد الإلكتروني info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG) 宣布创始人兼首席执行官 Pete O’Heeron 将在 2025 ThinkEquity Conference 于 2025年10月30日 在纽约市文华东方酒店进行演讲。公司演示定于 美国东部时间下午4:30 于10月30日进行，管理层将在整场活动中提供一对一的投资者会面。
如需获取演示详情或请求会议，请通过公司网站或发送邮件至 info@fibrobiologics.com 与公司联系。
- None.
- None.
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 2025 ThinkEquity Conference taking place October 30 at the Mandarin Oriental in New York City.
FibroBiologics will deliver a company presentation at 4:30 p.m. ET on October 30 and will be available for one-on-one investor meetings throughout the event.
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When will FibroBiologics (FBLG) present at the 2025 ThinkEquity Conference?
Who from FibroBiologics (FBLG) will present at the ThinkEquity Conference?
Where is the 2025 ThinkEquity Conference where FibroBiologics (FBLG) will present?
How can investors request a one-on-one meeting with FibroBiologics (FBLG) at the conference?
Will FibroBiologics (FBLG) cover clinical development updates in the October 30 presentation?
Where can I find more information about FibroBiologics (FBLG) presentation logistics for October 30, 2025?
